News

Psyence Biomed's Strategic Direction and Acquisition Update

Psyence Biomed's Strategic Direction and Acquisition Update

Psyence Biomed's Strategic Direction and Acquisition Update

Psyence Biomedical Ltd. (NASDAQ: PBM), renowned for its groundbreaking work in psilocybin-based therapeutics, has provided an update regarding its reevaluation of the acquisition of Clairvoyant Therapeutics, Inc. Following a comprehensive due diligence process, the company has decided to halt plans to proceed with the acquisition at this moment. This decision reflects Psyence's commitment to ensuring strategic alignment with its goals and the overall success of its operations.

Advancing Clinical Trials and Research

Despite the setback in the acquisition, Psyence Biomed is moving forward vigorously with its Phase IIb clinical trial. This trial involves utilizing nature-derived psilocybin in conjunction with psychotherapy to potentially treat Adjustment Disorder, specifically in patients facing life-limiting cancer diagnoses in Palliative Care. The anticipation for patient randomization in the upcoming quarter is promising, with topline data expected to be reported in the latter half of 2025.

Focused Development in Substance Use Disorders

Adding to its robust pipeline, Psyence Biomed is also progressing with a development program addressing Substance Use Disorders (SUDs), particularly focused on Alcohol Use Disorder (AUD). This critical initiative emphasizes the company's commitment to tackling addiction through innovative therapeutic solutions.

Collaboration with PsyLabs

To further bolster its AUD program, Psyence has announced a major step forward: a worldwide exclusive royalty-bearing intellectual property licensing agreement with PsyLabs. PsyLabs specializes in the production of highly purified psychedelic active pharmaceutical ingredients and extracts, enhancing Psyence's capabilities in developing effective treatment methodologies.

Upcoming Stake Acquisition and Strategic Growth

In a strategic growth maneuver, Psyence Biomed is also pursuing an acquisition of an 11.13% stake in PsyLabs. This prospective acquisition illustrates its vision of evolving into a leading, vertically integrated developer of psychedelic-based therapies. Due diligence is underway, and updates regarding this significant move will be announced soon.

Vision of Leadership in Psychedelic Therapeutics

Dr. Neil Maresky, M.D., Chief Executive Officer of Psyence Biomed, expressed his thoughts: “With the completion of our due diligence, it is unfortunate that we could not close the acquisition of Clairvoyant. The excitement for our development programs, especially concerning Adjustment Disorder and AUD, remains high. We are committed to achieving our milestones and continually look to explore new opportunities that align with our clinical strategy.”

About Psyence Biomed

Psyence Biomedical Ltd. (NASDAQ: PBM) holds a unique position in the biopharmaceutical space, being one of the few companies dedicated to developing psychedelic-based pharmaceutical therapeutics. As the pioneering biotechnology firm focused on nature-derived psilocybin, Psyence is addressing significant unmet patient needs in mental health care, particularly in Palliative Care settings.

Contact Information and Future Outlook

For further inquiries, individuals can reach Psyence Biomed through their designated channels. This includes general inquiries to info@psyencebiomed.com or through media inquiries at media@psyencebiomed.com. Investors can also contact Jeremy Feffer, Managing Director of LifeSci Advisors, at jfeffer@lifesciadvisors.com.

Frequently Asked Questions

What prompted Psyence Biomed to halt the acquisition?

The decision was made after a thorough due diligence process, indicating that it wasn't aligned with the company's strategic goals at this time.

What are the current clinical trials that Psyence Biomed is involved in?

Psyence Biomed is actively conducting a Phase IIb trial to study nature-derived psilocybin for treating Adjustment Disorder in patients with terminal illnesses.

How is Psyence Biomed addressing Substance Use Disorders?

They are advancing a program focused on Alcohol Use Disorder (AUD) and have secured a licensing agreement with PsyLabs to enhance their development efforts.

What future acquisitions does Psyence Biomed have planned?

Psyence Biomed plans to acquire an 11.13% stake in PsyLabs, reinforcing its commitment to developing integrated psychedelic therapeutics.

How can investors stay in touch with Psyence Biomed?

Investors can contact Jeremy Feffer at LifeSci Advisors for inquiries or updates regarding investment opportunities and developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading